Patient-specific dosimetry calculations using mathematic models of different anatomic sizes during therapy with 111In-DTPA-D-Phe 1-octreotide infusions after catheterization of the hepatic artery

Journal of Nuclear Medicine

Volumn 47, Issue 9, 2006, Pages 1476-1482

  Kontogeorgakos, Dimitrios K ^a   Dimitriou, Panagiotis A ^a   Limouris, Georgios S ^a   Vlahos, Lambros J ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

111In DTPA D Phe 1 octreotide; Dosimetry; Hepatic artery catheterization; Neuroendocrine tumors; Peptide therapy

Indexed keywords

DIETHYLENE TRIAMINEPENTAACETIC ACID DEXTRO 1 PHENYLALANINE OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PENTETREOTIDE; SOMATOSTATIN;

ADULT; AGED; ARTERY CATHETERIZATION; ARTICLE; BLADDER MUCOSA; BONE MARROW; CLINICAL ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; DRUG INFUSION; FEMALE; HEPATIC ARTERY; HUMAN; KIDNEY; LIVER; MALE; MATHEMATICAL MODEL; MONTE CARLO METHOD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE; SPLEEN; TISSUE DISTRIBUTION; TREATMENT PLANNING; WHOLE BODY SCINTISCANNING; BIOLOGICAL MODEL; BODY BURDEN; BODY SIZE; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; INTRAARTERIAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MIDDLE AGED; NEUROENDOCRINE TUMOR; RADIOMETRY; RELATIVE BIOLOGIC EFFECTIVENESS; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BODY BURDEN; BODY SIZE; COMPUTER SIMULATION; FEMALE; HEPATIC ARTERY; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INFUSIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEUROENDOCRINE TUMORS; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RELATIVE BIOLOGICAL EFFECTIVENESS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN;

EID: 33750579701     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
2. 1]-octreotide: a case history. Ann N Y Acad Sci. 1994;733:496-506.
3. Krenning EP, Kooij PPM, Pauwels S, et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion. 1996;57:57-61.
4. Krenning EP, de Jong M, Kooij PPM, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy [abstract]. Ann Oncol. 1999;10(suppl):S23.
5. Limouris GS, Dimitropoulos N, Kontogeorgakos D, et al. Evaluation of the therapeutic response to In-111-DTPA-octreotide based targeted therapy in liver metastatic neuroendocrine tumors according to CT/MRI/US findings. Cancer Biother Radiopharm. 2005;20:215-217.
6. Inoue Y, Ohtake T, Yoshikawa K, Nishikawa J, Sasaki Y. Estimation of dead time in imaging human subjects. Eur J Nucl Med. 1998;25:1232-1237.
7. Clairand I, Bouchet LG, Ricard M, Durigon M, Di Paola M, Aubert B. Improvement of internal dose calculations using mathematical models of different adult heights. Phys Med Biol. 2000;45:2771-2785.
8. de la Grandmaison GL, Clairand I, Durigon M. Organ weight in 684 adult autopsies: new tables for a Caucasoid population. Forensic Sci Int. 2001;119:149-154.
9. Cristy M, Eckerman KF. Specific Absorbed Fractions of Energy at Various Ages from Internal Photon Sources. Oak Ridge, TN: Oak Ridge National Laboratory; 1987:V1-V7. Report ORNL/TM-8381.
10. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(suppl):37S-61S.
11. Thomas SR, Stabin MG, Chin-Tu C, et al. MIRD pamphlet no. 14: a dynamic urinary bladder model for radiation dose calculations. J Nucl Med. 1992;33:783-802.
12. 90Y-DOTATOC. Eur J Nucl Med. 1999;28:877-886.
13. Snyder WS, Ford MR, Warner GG, Watson SB. "S" Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs: MIRD Pamphlet No. 11. New York, NY: Society of Nuclear Medicine; 1975.
14. Zaidi H, Sgouros G, eds. Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine. Bristol, U.K.: IOP Publishing Ltd.; 2003:95-102.
15. Marinelli L, Quimby E, Hine G. Dosage determinationwith radioactive isotopes II: biological considerations and practical applications. Nucleonics. 1948;2:44-49.
16. 131I-MIBG. J Nucl Med. 2001;42:1713-1721.
17. Boerman OC, Oyen WJG, Corstens FHM. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med. 2001;28:1447-1449.
18. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
19. 0] octreotide in patients. Eur J Nucl Med. 2001;28:1319-1325.
20. Krenning EP, Bakker WH, Kooij PPM, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-tyr-3-octreotide. J Nucl Med. 1992;33:652-658.
21. 1-octreotide in midgut carcinoid syndrome. J Nucl Med. 1996;37:1519-1521.
22. Stabin M, Kooij PPM, Bakker WH, et al. Radiation dosimetry for indium-111-pentetreotide. J Nucl Med. 1997;38:1919-1922.
23. International Basic Safety Standards for Protection Against Ionizing Radiation and for the Safety of Radiation Sources. Vienna, Austria: IAEA; 1996:51. Safety series no. IAEA 115.